BDBM538963 US11254668, Example 306::US11254668, Example 307

SMILES Nc1cc(n[nH]1)-c1cc(-c2cnn(n2)C2(CC#N)CC(C2)C#N)c2cccnc2c1

InChI Key InChIKey=NBGSHOJBNGEXJJ-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 538963   

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM538963(US11254668, Example 307 | US11254668, Example 306)
Affinity DataIC50: 7nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM538963(US11254668, Example 307 | US11254668, Example 306)
Affinity DataIC50: 14nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM538963(US11254668, Example 307 | US11254668, Example 306)
Affinity DataIC50: 30nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM538963(US11254668, Example 307 | US11254668, Example 306)
Affinity DataIC50: 49nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM538963(US11254668, Example 307 | US11254668, Example 306)
Affinity DataIC50: 174nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM538963(US11254668, Example 307 | US11254668, Example 306)
Affinity DataIC50: 255nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM538963(US11254668, Example 307 | US11254668, Example 306)
Affinity DataIC50: 1.93E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM538963(US11254668, Example 307 | US11254668, Example 306)
Affinity DataIC50: 9.16E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent